TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), and Algorithme Pharma (“Algorithme”) today announced that they have completed the multiplexed proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds using SQI’s Ig_PLEX™ multiplexing technology. SQI and Algorithme jointly presented the results of the proof of concept studies at the recent 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore held 18-20 March.
